Stock Track | Harmony Biosciences Surges 6% After Earnings Beat, Value Outlook

Stock Track11-01

Shares of Harmony Biosciences Holdings, Inc. (HRMY) soared 6.01% on Thursday, November 1st, following the release of the company's latest quarterly results and renewed interest from value investors.

In its earnings report, Harmony Biosciences reported a profit of $0.79 per share, surpassing analyst estimates by 19%. While revenues of $186 million were in line with expectations, the earnings beat was seen as a positive surprise by the market. However, analysts slightly trimmed their earnings per share forecasts for 2025 to $3.17, down from $3.26 previously, despite keeping revenue projections unchanged.

Separately, a value investing analysis highlighted Harmony Biosciences as potentially undervalued based on various valuation metrics. The stock's price-to-book, price-to-sales, and price-to-cash flow ratios all appeared attractive compared to industry averages. This renewed interest from value investors likely also contributed to the stock's surge on Thursday.

Overall, the combination of better-than-expected quarterly earnings and increased investor attention due to Harmony Biosciences' perceived undervaluation helped fuel the significant price movement. While analysts moderated their earnings outlook slightly, the company's solid revenue growth prospects and valuation multiples suggest the market sees further upside potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121087399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121087399","market":"us","top_or_hot":-1,"title":"Stock Track | Harmony Biosciences Surges 6% After Earnings Beat, Value Outlook","media":"Stock Track","content":"<p>Shares of Harmony Biosciences Holdings, Inc. (HRMY) soared 6.01% on Thursday, November 1st, following the release of the company's latest quarterly results and renewed interest from value investors.</p>\n\n<p>In its earnings report, Harmony Biosciences reported a profit of $0.79 per share, surpassing analyst estimates by 19%. While revenues of $186 million were in line with expectations, the earnings beat was seen as a positive surprise by the market. However, analysts slightly trimmed their earnings per share forecasts for 2025 to $3.17, down from $3.26 previously, despite keeping revenue projections unchanged.</p>\n\n<p>Separately, a value investing analysis highlighted Harmony Biosciences as potentially undervalued based on various valuation metrics. The stock's price-to-book, price-to-sales, and price-to-cash flow ratios all appeared attractive compared to industry averages. This renewed interest from value investors likely also contributed to the stock's surge on Thursday.</p>\n\n<p>Overall, the combination of better-than-expected quarterly earnings and increased investor attention due to Harmony Biosciences' perceived undervaluation helped fuel the significant price movement. While analysts moderated their earnings outlook slightly, the company's solid revenue growth prospects and valuation multiples suggest the market sees further upside potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harmony Biosciences Surges 6% After Earnings Beat, Value Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harmony Biosciences Surges 6% After Earnings Beat, Value Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-01 23:46 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Harmony Biosciences Holdings, Inc. (HRMY) soared 6.01% on Thursday, November 1st, following the release of the company's latest quarterly results and renewed interest from value investors.\n...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRMY","symbol_name":"Harmony Biosciences Holdings, Inc.","start_time":0,"source_url":"","article_id":"1121087399","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121087399","pubTimestamp":1730476001,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Harmony Biosciences Holdings, Inc.  soared 6.01% on Thursday, November 1st, following the release of the company's latest quarterly results and renewed interest from value investors.In its earnings report, Harmony Biosciences reported a profit of $0.79 per share, surpassing analyst estimates by 19%. While revenues of $186 million were in line with expectations, the earnings beat was seen as a positive surprise by the market. However, analysts slightly trimmed their earnings per share f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc."},"translate_title":"股票轨迹Harmony Biosciences在盈利超出预期和价值前景后飙升6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1},"content_text":"Shares of Harmony Biosciences Holdings, Inc. (HRMY) soared 6.01% on Thursday, November 1st, following the release of the company's latest quarterly results and renewed interest from value investors.\nIn its earnings report, Harmony Biosciences reported a profit of $0.79 per share, surpassing analyst estimates by 19%. While revenues of $186 million were in line with expectations, the earnings beat was seen as a positive surprise by the market. However, analysts slightly trimmed their earnings per share forecasts for 2025 to $3.17, down from $3.26 previously, despite keeping revenue projections unchanged.\nSeparately, a value investing analysis highlighted Harmony Biosciences as potentially undervalued based on various valuation metrics. The stock's price-to-book, price-to-sales, and price-to-cash flow ratios all appeared attractive compared to industry averages. This renewed interest from value investors likely also contributed to the stock's surge on Thursday.\nOverall, the combination of better-than-expected quarterly earnings and increased investor attention due to Harmony Biosciences' perceived undervaluation helped fuel the significant price movement. While analysts moderated their earnings outlook slightly, the company's solid revenue growth prospects and valuation multiples suggest the market sees further upside potential.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121087399"}